Skin And Skin Structure Infections by S.Pneumoniae- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014

Skin And Skin Structure Infections by S.Pneumoniae- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 is a new market research publication announced by Reportstack. The report provides comprehensive insights about phase III pipeline drugs and marketed drugs across the indication. A key objective of the report is to establish the understanding for API Manufacturers for marketed and Phase III pipeline drugs across the different countries and regions. While the leading brands, companies and chemicals are considered thoroughly, the report also provides details on the drug master filings across the US, Europe and Asia specifically China and India. The research, analysis also presents the global sales forecasts data till 2015. The report is also giving insight about the patent and exclusivity details of all the drugs across the indication. 

Data Sources

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Scope

• A snapshot of the global Market therapeutics scenario for Skin And Skin Structure Infections by S.Pneumoniae.

• A review of the marketed products under prescription for Skin And Skin Structure Infections by S.Pneumoniae, regulatory information and marketing status.

• Coverage of global patent coverage and detailed commentaries on the US patent challenges. 

• Graphical representation of investigational products for patent expiry and market exclusivities across the globe.

• Product profiles for marketed products for Skin And Skin Structure Infections by S.Pneumoniae with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.

• Coverage of API Manufacturers for Skin And Skin Structure Infections by S.Pneumoniae drugs in the United States, Europe and Asian Regions with location details.

• Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Skin And Skin Structure Infections by S.Pneumoniae drugs.

• Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Skin And Skin Structure Infections by S.Pneumoniae drugs.

• Coverage of Skin And Skin Structure Infections by S.Pneumoniae Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.

• Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.

• Key discontinued Marketed products.

• Global Sales Figure from 2011-2015.

Reasons to Buy

• Evaluate the marketing status and exclusivity details of Skin And Skin Structure Infections by S.Pneumoniae key products to exploit opportunities for generic drug development opportunities.

• Identify and understand important and diverse types of therapeutics under Phase III development for Skin And Skin Structure Infections by S.Pneumoniae.

• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to ‘Disease’.

• API intelligence over marketed drugs for Skin And Skin Structure Infections by S.Pneumoniae and gaining primary intelligence over active ingredients manufacturers across the globe.

• API intelligence over leading Phase III pipeline drugs.

• Develop and designstrategies by identifying the API manufacturers for Phase III pipeline products to enhance and expand business potential and scope.

• Understanding the scope of the Phase III Drugs with nil regulatory filings.

• Understanding the chemical route of synthesis of approved drugs for Skin And Skin Structure Infections by S.Pneumoniae.

• Uncovering opportunities in the rapidly growing the US markets.

Companies Mentioned

Merck & Co., Inc. Eli Lilly and Company AbbVie Inc. Hospira, Inc. Bayer HealthCare Pharmaceuticals Aqua Pharmaceuticals, LLC Pfizer Inc. Cubist Pharmaceuticals, Inc. Arbor Pharmaceuticals, Inc. Bayer AG Warner Chilcott Company, Inc. Bayer Inc. Actavis, Inc. GlaxoSmithKline Inc. Hikma Pharmaceuticals PLC Sandoz Inc. Mutual Pharmaceutical Company, Inc. Par Pharmaceutical Companies, Inc. GlaxoSmithKline plc SICOR Pharmaceuticals, Inc. Apothecon Inc B. Braun Medical Inc. sanofi-aventis U.S. LLC. Baxter Healthcare Corporation King Pharmaceuticals Ltd Wyeth (Inactive) Bristol-Myers Squibb Company AstraZeneca PLC Janssen Pharmaceuticals, Inc. Astellas Pharma US, Inc. Ersana, Inc. Abraxis BioScience, Inc. Triax Pharmaceuticals, LLC Lederle Laboratories Abbott Laboratories Wyeth Pharmaceuticals, Inc. B. Braun Avitum AG Warner Chilcott Plc LNK International Inc. Paddock Laboratories, Inc.

To view the table of contents and know more details please visit Skin And Skin Structure Infections by S.Pneumoniae- Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014